[go: up one dir, main page]

ECSP11011501A - 17 -alquil-17 -oxi-estratrienos - Google Patents

17 -alquil-17 -oxi-estratrienos

Info

Publication number
ECSP11011501A
ECSP11011501A EC2011011501A ECSP11011501A ECSP11011501A EC SP11011501 A ECSP11011501 A EC SP11011501A EC 2011011501 A EC2011011501 A EC 2011011501A EC SP11011501 A ECSP11011501 A EC SP11011501A EC SP11011501 A ECSP11011501 A EC SP11011501A
Authority
EC
Ecuador
Prior art keywords
stratriens
quent
oxi
estratriennes
oxy
Prior art date
Application number
EC2011011501A
Other languages
English (en)
Inventor
Rolf Bohlmann
Hermann Kuenzer
Jens Hoffmann
Jan Huebner
Dieter Lang
Georg Kettschau
Michael Sander
Michael Gerisch
Tim Wintermantel
Philip Lienau
Nikolaus Heinrich
Silke Koehr
Karsten Denner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011501(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of ECSP11011501A publication Critical patent/ECSP11011501A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se relaciona con 17 alquil-17 -oxi-estratrienos de fórmula (I), con métodos para producirlos, con el uso de los 17 -alquil-17 -oxi-estratrienos para preparar fármacos y con preparaciones farmacéuticas que comprenden estos compuestos.
EC2011011501A 2009-06-04 2011-12-02 17 -alquil-17 -oxi-estratrienos ECSP11011501A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075249A EP2258375A1 (de) 2009-06-04 2009-06-04 17B-alkyl-17alpha-oxy-estratriene

Publications (1)

Publication Number Publication Date
ECSP11011501A true ECSP11011501A (es) 2012-01-31

Family

ID=41460961

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011501A ECSP11011501A (es) 2009-06-04 2011-12-02 17 -alquil-17 -oxi-estratrienos

Country Status (27)

Country Link
US (1) US20120157421A1 (es)
EP (2) EP2258375A1 (es)
JP (1) JP2012528808A (es)
KR (1) KR20120042827A (es)
CN (1) CN102802634A (es)
AR (1) AR076980A1 (es)
AU (1) AU2010256035A1 (es)
BR (1) BRPI1013017A2 (es)
CA (1) CA2764249A1 (es)
CL (1) CL2011003050A1 (es)
CO (1) CO6470855A2 (es)
CR (1) CR20110647A (es)
CU (1) CU20110224A7 (es)
DO (1) DOP2011000374A (es)
EA (1) EA201101703A1 (es)
EC (1) ECSP11011501A (es)
IL (1) IL216524A0 (es)
MA (1) MA33329B1 (es)
MX (1) MX2011012878A (es)
NZ (1) NZ596824A (es)
PE (1) PE20120318A1 (es)
SG (1) SG176630A1 (es)
TN (1) TN2011000617A1 (es)
TW (1) TW201103547A (es)
UY (1) UY32688A (es)
WO (1) WO2010139411A2 (es)
ZA (1) ZA201200036B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116041412A (zh) * 2023-01-13 2023-05-02 香港中文大学（深圳） 氟维司群衍生物及其制备方法、应用和治疗乳腺癌的药物
CN116535454A (zh) * 2023-04-28 2023-08-04 香港中文大学（深圳） 氟维司群类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
EP0310542B1 (de) 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
DE19510862A1 (de) 1995-03-16 1996-09-19 Schering Ag Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE10019171A1 (de) 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate

Also Published As

Publication number Publication date
CL2011003050A1 (es) 2012-06-15
AU2010256035A1 (en) 2011-12-22
WO2010139411A2 (de) 2010-12-09
CN102802634A (zh) 2012-11-28
KR20120042827A (ko) 2012-05-03
SG176630A1 (en) 2012-01-30
EP2258375A1 (de) 2010-12-08
CR20110647A (es) 2012-02-16
WO2010139411A3 (de) 2011-03-10
US20120157421A1 (en) 2012-06-21
EP2437746A2 (de) 2012-04-11
UY32688A (es) 2010-12-31
CO6470855A2 (es) 2012-06-29
MA33329B1 (fr) 2012-06-01
AR076980A1 (es) 2011-07-20
CA2764249A1 (en) 2010-12-09
MX2011012878A (es) 2012-01-12
TN2011000617A1 (en) 2013-05-24
JP2012528808A (ja) 2012-11-15
CU20110224A7 (es) 2012-04-15
ZA201200036B (en) 2013-06-26
IL216524A0 (en) 2012-02-29
PE20120318A1 (es) 2012-03-24
BRPI1013017A2 (pt) 2016-03-29
DOP2011000374A (es) 2012-01-15
EA201101703A1 (ru) 2012-06-29
TW201103547A (en) 2011-02-01
NZ596824A (en) 2013-07-26

Similar Documents

Publication Publication Date Title
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
ECSP13012519A (es) Compuestos sustituidos de benzamida
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
ECSP11011347A (es) Nicotinamida sustituida como moduladores KCNQ2/3
CR11861A (es) Compuestos organicos
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
MX2020012695A (es) Compuestos de benceno substituidos con arilo o heteroarilo.
ECSP099620A (es) Derivados de ciclohexano espirociclico
GT201400111A (es) Triazolopiridinas sustituidas
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
CU20080169A7 (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos.
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
NI201100034A (es) Uso de dronedarona para la preparación de un medicamento para la prevención de ictus o ataque isquémico transitorio.